GB2503148A - Biomarker panels diagnostic methods and test kits for ovarian cancer - Google Patents

Biomarker panels diagnostic methods and test kits for ovarian cancer Download PDF

Info

Publication number
GB2503148A
GB2503148A GB1316222.7A GB201316222A GB2503148A GB 2503148 A GB2503148 A GB 2503148A GB 201316222 A GB201316222 A GB 201316222A GB 2503148 A GB2503148 A GB 2503148A
Authority
GB
United Kingdom
Prior art keywords
ovarian cancer
test kits
diagnostic methods
biomarker panels
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1316222.7A
Other languages
English (en)
Other versions
GB201316222D0 (en
Inventor
Greg P Bertenshaw
Ping F Yip
Partha Seshalah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspira Womens Health Inc
Original Assignee
Vermillion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vermillion Inc filed Critical Vermillion Inc
Publication of GB201316222D0 publication Critical patent/GB201316222D0/en
Publication of GB2503148A publication Critical patent/GB2503148A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
GB1316222.7A 2011-02-24 2012-02-14 Biomarker panels diagnostic methods and test kits for ovarian cancer Withdrawn GB2503148A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161463870P 2011-02-24 2011-02-24
PCT/US2012/024997 WO2012115820A2 (en) 2011-02-24 2012-02-14 Biomarker panels, diagnostic methods and test kits for ovarian cancer

Publications (2)

Publication Number Publication Date
GB201316222D0 GB201316222D0 (en) 2013-10-30
GB2503148A true GB2503148A (en) 2013-12-18

Family

ID=46721396

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1316222.7A Withdrawn GB2503148A (en) 2011-02-24 2012-02-14 Biomarker panels diagnostic methods and test kits for ovarian cancer

Country Status (9)

Country Link
US (1) US20150031561A1 (ko)
EP (1) EP2678682A4 (ko)
KR (1) KR20140024860A (ko)
CN (1) CN103582815A (ko)
AU (1) AU2012220896B2 (ko)
CA (1) CA2828119A1 (ko)
DE (1) DE112012000990B4 (ko)
GB (1) GB2503148A (ko)
WO (1) WO2012115820A2 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104535765A (zh) 2009-03-12 2015-04-22 癌症预防和治疗有限公司 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
US20150004633A1 (en) * 2012-02-07 2015-01-01 Quest Diagnostics Investments Incorporated Assays and methods for the diagnosis of ovarian cancer
WO2014063743A1 (en) * 2012-10-25 2014-05-01 Association Pour La Recherche Thérapeutique Anti-Cancéreuse Methylglyoxal as a marker of cancer
CA3210220A1 (en) * 2013-05-10 2014-11-13 Johns Hopkins University Compositions for ovarian cancer assessment having improved specificity
CN104422768A (zh) * 2013-08-30 2015-03-18 广州瑞博奥生物科技有限公司 一种联合检测早期卵巢癌标志物的抗体芯片试剂盒
CN113403338A (zh) * 2014-03-28 2021-09-17 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
CA2981347A1 (en) * 2015-04-02 2016-10-06 Provista Diagnostics, Inc. Biomarkers for detection of ovarian cancer
CN105232060A (zh) * 2015-08-31 2016-01-13 陈琼 基于独立风险因子组合筛查的预警系统
US10823735B2 (en) * 2015-09-03 2020-11-03 The University Of Hong Kong Monoclonal antibody for predicting tamoxifen response in breast cancer patients
MA43342A (fr) * 2015-09-30 2018-08-08 Medimmune Ltd Compositions et procédé d'inhibition de cellules souches cancéreuses
JP6143920B1 (ja) * 2016-06-20 2017-06-07 国立研究開発法人国立がん研究センター 卵巣がんの予後診断マーカーとしてのｍｍｐ１遺伝子転写産物と検査法
CN107765011A (zh) * 2016-08-16 2018-03-06 华明康生物科技（深圳）有限公司 早期癌症筛查方法及试剂盒
CN107765012B (zh) * 2016-08-16 2020-10-27 华明康生物科技（深圳）有限公司 早期非小细胞肺癌筛查方法及试剂盒
CN107765013B (zh) * 2016-08-16 2021-04-02 华明康生物科技（深圳）有限公司 早期卵巢癌筛查方法及试剂盒
CN107765005B (zh) * 2016-08-16 2021-01-15 华明康生物科技（深圳）有限公司 早期小细胞肺癌筛查方法及试剂盒
CN110709936A (zh) * 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
CN107541499B (zh) * 2017-07-27 2020-04-14 山东兴瑞生物科技有限公司 一种靶向免疫检测点tnfr2的cik的制备及其应用
WO2019210052A1 (en) * 2018-04-27 2019-10-31 Laboratory Corporation Of America Holdings Methods and systems for determining the risk of developing ovarian cancer
WO2019224786A1 (en) * 2018-05-24 2019-11-28 Alize Pharma Iii Sas Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders
CN109342730A (zh) * 2018-12-07 2019-02-15 江苏省原子医学研究所 同时检测妇科肿瘤标志物her-2和he4的试纸条
JPWO2020203478A1 (ko) * 2019-04-02 2020-10-08
AU2020404453B2 (en) * 2019-12-20 2022-12-08 Hudson Institute of Medical Research CXCL10 binding proteins and uses thereof
KR102316178B1 (ko) * 2020-04-14 2021-10-22 서울대학교병원 난소암 환자의 암 재발율 또는 생존율 예측용 조성물
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
JP2023550278A (ja) * 2020-10-30 2023-12-01 エフ． ホフマン－ラ ロシュ アーゲー 胆管癌のマーカーとしてのｔｉｍｐ１
CN112816691B (zh) * 2021-02-08 2024-06-11 杭州市妇产科医院 一种人卵母细胞质量评价的方法
WO2022207685A1 (en) * 2021-04-01 2022-10-06 F. Hoffmann-La Roche Ag Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis
CN116879558B (zh) * 2023-09-05 2023-12-01 天津云检医学检验所有限公司 卵巢癌诊断标志物、检测试剂及检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075307A1 (en) * 2006-01-27 2009-03-19 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO2001099043A1 (en) 2000-06-19 2001-12-27 Correlogic Systems, Inc. Heuristic method of classification
IL153856A0 (en) 2000-07-18 2003-07-31 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1540010B8 (en) * 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
EP1649281A4 (en) 2003-08-01 2007-11-07 Correlogic Systems Inc MULTIPLE HIGH RESOLUTION SERUM PROTEOMIC CHARACTERISTICS FOR THE DETECTION OF OVARIAN CANCER
US20070042405A1 (en) * 2003-08-15 2007-02-22 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Enhanced diagnostic multimarker serological profiling
EP1723428A2 (en) * 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
WO2005094381A2 (en) 2004-04-01 2005-10-13 Rules-Based Medicine, Inc. Universal shotgun assay
WO2007005426A2 (en) 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
EP2982761B1 (en) * 2006-01-04 2017-10-04 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
WO2008118798A1 (en) * 2007-03-23 2008-10-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multimarker assay for early detection of ovarian cancer
JP2010532484A (ja) * 2007-06-29 2010-10-07 コレロジック システムズ，インコーポレイテッド 卵巣癌のための予測マーカー
US20100227335A1 (en) * 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010148145A1 (en) * 2009-06-16 2010-12-23 Fred Hutchinson Cancer Research Center Methods and kits for detecting ovarian cancer from blood
US20120171694A1 (en) * 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075307A1 (en) * 2006-01-27 2009-03-19 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE BRUIJN H. W. et al. Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated. Tumour Biol., 1998, vol.19, no.3, pp.160-166. See abstract. *
HURTEAU, J. A. et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer, Nov.1 1995, vol.76, no.9 pp.1615-1620. See abstract. *
SEDLACZEK, P. et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer, Nov.1 2002, Vol.95, No.9, pp.1886-1893. See the whole document *

Also Published As

Publication number Publication date
US20150031561A1 (en) 2015-01-29
EP2678682A4 (en) 2014-10-01
DE112012000990B4 (de) 2024-06-27
DE112012000990T5 (de) 2014-03-27
CA2828119A1 (en) 2012-08-30
WO2012115820A3 (en) 2013-03-14
AU2012220896A1 (en) 2013-09-05
GB201316222D0 (en) 2013-10-30
KR20140024860A (ko) 2014-03-03
WO2012115820A2 (en) 2012-08-30
EP2678682A2 (en) 2014-01-01
AU2012220896B2 (en) 2016-11-24
CN103582815A (zh) 2014-02-12

Similar Documents

Publication Publication Date Title
GB2503148A (en) Biomarker panels diagnostic methods and test kits for ovarian cancer
MY150234A (en) Predictive markers for ovarian cancer
GB201021289D0 (en) Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
EA201890925A3 (ru) Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
MX2013005067A (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX351779B (es) Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
AU2012356133A8 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
BR112012030587A2 (pt) métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
IN2014CN04326A (ko)
EA201370063A1 (ru) Фосфолипидом рака
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
EA201401201A1 (ru) Способ
AU2012236134A8 (en) Biomarkers for predicting sensitivity to cancer treatments
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
IN2015DN01646A (ko)
IN2014DN08430A (ko)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)